HAE
HaemoneticsBNYSE / Health Care Equipment & Services
Last Price
At close
2026-06-03
Current thesis
The post-earnings bull read is that Haemonetics closed FY26 with better-than-feared core growth: Q4 adjusted EPS slightly beat the Zacks-based snapshot, FY27 guidance implies re-acceleration, and Hospital plus Plasma are carrying the portfolio while Vivasure adds another interventional growth leg.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +24.1.
What can break
Adjusted gross margin also fell 50 bps, with less favorable mix and tariff impacts called out in the earnings release [#8-K-2026-05-07].
Momentum
72
Value
66
Sentiment
41
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $66.00 · Bull $78.00 · Bear $46.00
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $88.00
Why
Momentum72 · Δ7d +24.1
Value66 · Δ7d +0.0
Sentiment41 · Δ7d +1.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
72
34% active weight
Current posture
7d trendImproving
Δ7d
+24.1
Δ21d
+48.5
Value
66
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-1.1
Sentiment
41
33% active weight
Current posture
7d trendImproving
Δ7d
+1.3
Δ21d
-15.1
Why this grade
Composite grade B. Momentum 71.9 / Value 65.9 / Sentiment 41.2
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$3.02B
Beta
0.28
Shares Out
46.81M
P/E (TTM)
24.0
P/S (TTM)
2.89
P/FCF (TTM)
18.08
Rev YoY
-5.3%
EPS YoY
+22.9%
Gross Margin
+58.5%
Op Margin
+18.3%
Net Debt
$918.03M
Current Ratio
1.64
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology